Ocular Therapeutix, Inc. OCUL
Updated: 16 Jun 2026
No signal published yet
We already track Ocular Therapeutix and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Ocular Therapeutix, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Ocular Therapeutix free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
Ocular Therapeutix is scheduled to host an Investor Day on June 17, 2026, to provide updates on its clinical pipeline, including the AXPAXLI and HELIOS-3 programs. In May 2026, the company reported positive Phase 3 results for AXPAXLI in wet AMD and initiated the SOL-X long-term extension trial. These developments follow the company's Q1 2026 financial report which showed a cash position of $666.7 million.
What Firelda Watch includes for Ocular Therapeutix, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Ocular Therapeutix, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Ocular Therapeutix free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more